P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1Niels W.C.J. van de Donk, María‐Victoria Mateos, Alfred L. Garfall et al.|HemaSphere|2023Cited by 5